CART is a novel islet regulatory peptide.

Nils Wierup and Frank Sundler

Department of Experimental Medical Science, Division of Diabetes, Metabolism, and Endocrinology, Lund University, Lund, Sweden.

Corresponding author:

Nils Wierup, PhD
Lund University
Department of Experimental Medical Science
Division of Diabetes, Metabolism, and Endocrinology
Unit of Neuroendocrine Cell Biology
BMC F10
22 184, Lund
Sweden
Phone: +46 46 222 36 30
Fax: +46 46 222 45 46
e-mail: nils.wierup@med.lu.se
ABSTRACT

CART peptides have emerged as important islet regulators. CART is expressed both in islet endocrine cells and in parasympathetic and sensory nerves innervating the islets. In adult rats the intra-islet expression of CART is limited to the somatostatin producing δ-cells, while in adult mice CART is mainly expressed in nerve fibers. During development islet CART is upregulated; in rats in almost all types of islet endocrine cells, including the insulin producing β-cells, and in mice mainly in the α-cells. This pattern of expression peaks around birth.

CART is also expressed in human pancreatic nerves and in islet tumours where the expression level of CART may be related to the degree differentiation of the tumour. Interestingly, in several rat models of type 2 diabetes CART expression is robustly upregulated in the β-cells, and is prominent during the phase of beta cell proliferation and hypertrophy. While CART inhibits glucose stimulated insulin secretion from rat islets it augments insulin secretion amplified by cAMP. Mice lacking CART, on the other hand, have islet dysfunction, and humans with a missense mutation in the cart gene are prone to develop type 2 diabetes. These data favour a role of CART in normal islet function and in the pathophysiology of type 2 diabetes.
INTRODUCTION

The pancreatic islets contain four main cell types; insulin-producing β-cells, glucagon-producing α-cells, somatostatin-producing δ-cells and pancreatic polypeptide (PP) producing PP-cells. Recently a fifth islet cell type, the ghrelin cell, was identified in human and rodent islets [34; 36]. Further, gastrin producing cells are present in the developing rat islets [22]. In addition to the peptides expressed in “own” cell types a great number of regulatory peptides are more promiscuously expressed in the developing islets and coexist with the established hormones, some of them transiently during development and/or when the islets are challenged, e.g. in type-2 diabetes. Such co-expressed peptides in islet cells include neuropeptide Y (NPY), peptide YY (PYY), islet amyloid polypeptide (IAPP), and calcitonin gene-related peptide (CGRP) which have been reviewed elsewhere [25]. Many of these peptides are also present in nerves innervating the pancreas [reviewed in 1]. Expression of CART in endocrine cells has been reported in other organs, including pituitary [7; 9], adrenal medulla [7; 11; 20], and in the antral gastrin producing G-cells in the stomach [12]. Here we review the distribution of CART in the pancreas and functional islet related data obtained so far. Special attention has been given to the distribution pattern of CART in the islets and to the role of CART in islet function.

CART distribution and expression in the pancreas.

Fetal, neonatal and adult rodent islet cells.

In normal adult rats CART is mainly expressed in the somatostatin producing δ-cells and in pancreatic neurons [18; 35]. However, during development CART is highly expressed also in β-cells (Fig. 1), α-cells, PP-cells, but somewhat surprisingly, not in the ghrelin cells [35]. In the rat, islet ghrelin cells deviate from the other islet cells in that they are only present during
fetal and neonatal development and virtually disappear a few weeks after birth [36]. A similar
developmental pattern holds also for the gastrin producing islet cells, but in contrast to the
ghrelin cells a great proportion of the gastrin producing cells express CART [22; 35]. The
expression of CART in the islet gastrin cells is reminiscent of the CART expression in the
gastric G-cells of adult rats [12]. In adult mouse islets only very few δ-cells are weakly CART
IR [38]. However in developing mouse islets CART is upregulated in the α-cells (Fig 2C). In
contrast to the developing rat islets, virtually no CART immunoreactive (IR) β-cells (Fig 2A-
B), and no CART IR δ-cells (Fig 2B and D) were detected. In addition, a small subpopulation
of the PP-cells and the ghrelin cells were CART IR.

*Islets of rodent models of type-2 diabetes*

CART is markedly upregulated in the β-cells of several type-2 diabetes models of rats and
mice. One such model is dexamethasone (DEX) induced diabetes [30]. Rats treated with DEX
in a high dose for 12 days display ten-fold higher relative number of CART IR β-cells (Fig 3)
and ten-fold higher CART mRNA expression compared to control rats [39]. The GK rat, a
polygenic model of inherited type-2 diabetes [14], displays thirty-fold higher relative number
of CART IR β-cells paralleled by a robust increase in CART mRNA expression compared to
the Wistar control rats [39]. CART is robustly upregulated also in the β-cells of ob/ob mice,
and Zucker Diabetic Fatty (ZDF) rats [37]. Altogether, CART is upregulated in the β-cells of
four, mechanistically different, models of typ-2 diabetes in two different species.
Interestingly, in the CNS CART is positively regulated by leptin, and leptin deficient animals
have decreased expression of CART in the CNS [13; 21]. Our finding of increased expression
of β-cell CART in ZDF rats and ob/ob mice, which have disrupted leptin signalling, are
therefore somewhat surprising and quite opposite of the central effect. To our knowledge this
is the first finding of upregulated CART in animals with deficient leptin signalling.
Investigation of the subcellular localisation of CART using TEM and immunogold labelling on ultrathin sections revealed that anti-CART labelling in DEX rats localised to the secretory granules of both β-cells and δ-cells [39]. This is a strong indication that CART is secreted from both β-cells and δ-cells, and, in addition, it provides the morphological substrate for co-secretion of CART and insulin as well as CART and somatostatin.

**Neurons**

In addition to endocrine cells, CART is widely expressed in both nerve fibers and in nerve cell bodies in pancreatic ganglia, sometimes forming neuroislet complexes. The CART expressing neurons are particularly prominent in the mouse pancreas during development (Fig. 2A). In both rat and mouse pancreas CART is present in parasympathetic (VIP-containing) and sensory (CGRP-containing) nerves [35; 38]. In the pancreas the parasympathetic nerves are known to activate insulin secretion [1]. Interestingly, CART is released in pigs upon vagal stimulation [32]. Hence, CART may be involved in the regulation of parasympathetic control of islet function. The finding of CART in the peripheral endings of sensory neurons further suggests a role for CART in the regulation of insulin secretion since these neurons are proposed to exert a tonic inhibition on insulin secretion [1]. Further, it has been reported that CART stimulates rat pancreatic exocrine secretion, and that the effect is reduced after blocking parasympathetic transmission with atropine and abolished after vagotomy [8]. These findings suggest an action of CART on parasympathetic nerve transmission in the pancreas. Thus, another function of CART in pancreatic nerves may be to modulate neuronally mediated exocrine pancreatic secretion. Although CART is localised to preganglionic sympathetic neurons at other sites [11], CART is absent from pancreatic sympathetic nerve fibers [35]. The data on neurotrophic properties of CART on certain neurons in vitro [23] is intriguing and a role for CART as a survival/differentiation factor for pancreatic neurons is not inconceivable.
**CART in human pancreas**

Data on CART in the human pancreas are scarce. We have found CART in intrapancreatic neurons and in islet cells during fetal development (own unpublished observations). These findings are of great importance and provides anatomical prerequisites for a function of CART in the regulation of pancreatic endocrine and exocrine processes also in humans. In addition, we have found CART to colocalise with insulin in human insulinomas. Interestingly, the expression of CART seems to be related to the degree of differentiation of the tumour. Thus, highly differentiated tumours with high insulin IR also displayed high CART IR, whereas less differentiated tumours with only weak insulin IR were devoid of CART IR (Fig. 4). Hence, CART may be a marker of certain islet tumours. A potential role for CART in tumour differentiation remains to be elucidated.

**CART regulates islet hormone secretion**

The extensive expression of CART in the islets and in pancreatic neurons points to a role for CART in islets function. Interestingly therefore, CART regulates islet hormone secretion from clonal β-cells and from isolated rat islets. Thus, under conditions of cAMP-amplified glucose-stimulated insulin secretion (GSIS), CART acts to boost insulin secretion even further [39]. This effect could be explained by a further increase in intracellular cAMP and subsequently exaggerated activation of PKA. On the other hand, in the absence of cAMP elevating agents, i.e. with glucose alone as insulin secretagogue, CART caused decreased insulin secretion from isolated rat islets [39]. This reduction of insulin secretion could be caused by the parallel drop in glucagon, which is known to stimulate insulin secretion via cAMP. In addition, CART lowered also somatostatin secretion from isolated rat islets in the absence of cAMP elevating agents. One would expect this to result in increased GSIS;
however, since somatostatin inhibits both insulin and glucagon, lowered somatostatin secretion does not necessarily result in increased insulin secretion.

Our hypothesis that the decreased glucagon secretion is responsible for the drop in GSIS gains support from our data on clonal β-cells. Here CART was without effect under solely glucose stimulated conditions. Together it seems that the stimulatory effect of CART on GSIS is dependent on a high intracellular cAMP level. Our finding [39] that CART increased also IBMX stimulated GSIS from clonal β-cells indicates that not only activation of adenylate cyclase by forskolin or GLP-1, but also inhibition of cAMP degradation can produce this state of high cAMP necessary for CART to boost GSIS. It also indicates that the effect of CART is not explained by modulation of cAMP breakdown. Based on the assumption that a certain level of cAMP is needed to trigger the stimulating effect of CART on GSIS one may speculate the following. When glucagon secretion is lowered, the β-cell concentration of cAMP is decreased and, thus, CART is not able to exert a stimulatory effect on GSIS. The decreased GSIS may therefore be explained by the combination of the decreased glucagon effect itself on GSIS and inability of CART to stimulate GSIS since the level of cAMP is too low. Our data indicating an inhibitory effect of CART on GSIS in the absence of cAMP elevating agents are in agreement with those of Wang et al [33]. On the other hand Colombo et al [6] reported no effect of CART on GSIS. Further, studying isolated perfused porcine pancreas, Tornoe et al [32] were unable to detect any effects of CART on insulin or glucagon secretion. There is no ready explanation for the divergent data; one explanation could be that there are CART-related species differences between rat and pig. The documented reduction in plasma insulin and leptin caused by chronic central infusion of CART in the rat [28] is intriguing and raises questions about the action of CART on the islets in intact animals. Further studies are needed to clarify the actual roles for CART on islet hormone secretion in vivo. In view of the effects of CART on GLP-1 mediated GSIS, future islet studies of possible
effect of CART on GLP-1 stimulated β-cell proliferation and/or differentiation [5; 16] would be of great interest. In view of successful clinical trials with GLP-1 [2; 17] the potentiating effect of CART on GLP-1 mediated GSIS is intriguing, and the potential of CART in combination wit GLP-1 in the treatment of type-2 diabetes needs further investigation.

Absence of CART

CART KO mice develop increased body weight after 40 weeks on a normal diet [38] and, in another strain of CART KO mice, at the age of 17 weeks when fed a high fat diet for 14 weeks [3]. In addition, absence of CART results in impaired GSIS and impaired glucose elimination explained by islet dysfunction. Importantly, the defect is apparent both in vivo and in isolated islets already in young CART-deficient mice with no difference in body weight from wild type mice. Although the islets in CART KO animals appear normal with respect to size, islet hormone expression and intra-islet cell topography, the β-cells have markedly reduced expression of GLUT-2 and PDX-1. GLUT-2 is a major determinant of glucose uptake in beta cells [31] whereas PDX-1 is of importance for beta cell development and insulin gene expression [19; 27]. Notably, genetic deletion of either GLUT-2 [15] or PDX-1 [19] is associated with defective insulin secretion and glucose intolerance. Thus, CART does not seem to be crucial for development of appropriate islet size or islet cell topography, but rather to the β-cell function. Although the decreased expression of PDX-1 and GLUT-2 may be secondary to the diabetic phenotype of the animals, a role for CART in maintenance of appropriate levels of these proteins cannot be ruled out. Together our data suggest that CART is necessary for maintaining normal islet function. In view of the potentiating effect of CART on cAMP mediated GSIS, studies of cAMP mediated insulin secretion in CART KO mice would be of great interest.
It is of notice in this context that humans with a missense mutation resulting in heterozygosity for CART were reported to have, in addition to obesity, a higher incidence of type-2 diabetes [10]. Thus it seems that also humans are susceptible for alterations in CART availability and lowering the gene dose to half is enough to result in increased type-2 diabetes incidence and obesity. It is, however, not possible to tell from that report whether the type-2 diabetes is secondary to the reported obesity or is due to a defect at the islet level. Interestingly, it seems that humans are more sensitive to CART than are mice, since CART heterozygous mice did not develop obesity when fed a normal laboratory diet (own unpublished observations). However, Asnicar et al [3] showed that while after feeding a high fat diet male CART heterozygous mice were of normal weight, females had slightly increased body weight.

A role for CART during development?

Given the fact that the islets are virtually flooded by CART during development, the role for CART as a regulator of islet hormone secretion during development remains to be elucidated. If so: does the inhibitory effect on glucagon secretion, leading to decreased insulin secretion or does the stimulatory effect on GLP-1 mediated insulin secretion predominate?

During fetal and neonatal development an array of insulin inhibitors are upregulated locally in the islets. Among such inhibitors are NPY, expressed in the β-cells perinatally [24; 26], and PYY, expressed mainly in α-cells and PP-cells during rodent ontogeny [4; 26]. It has been speculated that one function of this upregulation is to protect the fetus from hypoglycemia. This may be the function also for CART, which inhibits GSIS under basal conditions. On the other hand, CART stimulates GLP-1 mediated insulin secretion. Interestingly therefore Sjöholm et al [29] reported that although long-term GLP-1 in vitro increased insulin content in isolated fetal rat islets, GLP-1 did not affect short-term GSIS. This may indicate that the
GLP-1-islet axis is not functioning as in the adult animal; thus the main role for CART during fetal life could be to serve as an inhibitor of insulin secretion.

**Concluding remarks**

CART can now be added to the array of regulatory peptides that are involved in the complex regulation of islet function, and it is now established that CART is needed for maintaining normal islet function. It is also established that CART regulates islet hormone secretion, although other functions such as influence on islet growth and maintenance cannot be ruled out. An important information still lacking is how islet CART interacts with the many other locally expressed regulatory peptides. Although it is clear that CART is upregulated in β-cells of rodent models of type-2 diabetes, a role for CART in type-2 diabetes pathophysiology needs further investigation.

**ACKNOWLEDGEMENTS**

Grant supports from: Swedish Medical Research Council (Project No. 4499), The Swedish Royal Physiographic Society, Novo Nordic, Goljes Minne, Tore Nilsson, Åke Wibergs, and Gyllenstiernska Krapperup Foundations.

**FIGURE LEGENDS**

Fig 1. Low magnification immunofluorescence photomicrographs of fetal rat pancreas (E20) double immunostained for CART (A) and insulin (B); merged in C. Scale bar = 100μm.

CART is expressed in all islets, predominantly in the insulin producing β-cells.

Fig 2. Neonatal mouse islets. A: Double immunostaining for CART (red) and insulin (green). CART immunoreactive cells (exemplified with big arrow-heads) are different from the
insulin-producing β-cells. CART is highly expressed in pancreatic nerve fibers (exemplified with small arrow-heads) and ganglionic nerve cell bodies (indicates with g) within neuro islet complexes. C: Double immunostaining for CART (red) and glucagon (green). CART is expressed in a subpopulation of the glucagon-producing α-cells (colocalisation exemplified with arrow-heads). B: Double immunostaining for CART (red) and insulin (green). D: the same section as in B after wash and immunostaining for somatostatin (red). CART immunoreactive cells are different from the somatostatin-producing δ-cells. Arrowheads in D, point out the location of the indicated CART immunoreactive cells in B. Scale bar = 50μm.

Fig 3. Rat islets triple-immunostained for CART (A; E), somatostatin (B; F) and insulin (C; G); merged in D and H. Upper panel: Saline treated control rats. CART is mainly localised to the somatostatin-producing δ-cells. Lower panel: Dexamethasone-treated rats. CART is robustly upregulated in the insulin-producing β-cells. Scale bar = 20μm.

Fig 4. Human insulin producing islet tumors double immunostained for CART (A, D) and insulin (B, E); merged in C and F. CART immunoreactivity is seen in a tumour with highly differentiated, insulin-rich cells (A-C) but not in a tumour with less differentiated cells (D-F).
REFERENCES
